Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti (Q38356895)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti (English)

1 reference

Europe PubMed Central

2 September 2017

0 references

author name string

V A Gault

1

1 reference

Europe PubMed Central

2 September 2017

F P M O'Harte

2

1 reference

Europe PubMed Central

2 September 2017

P Harriott

3

1 reference

Europe PubMed Central

2 September 2017

M H Mooney

4

1 reference

Europe PubMed Central

2 September 2017

B D Green

5

1 reference

Europe PubMed Central

2 September 2017

P R Flatt

6

1 reference

Europe PubMed Central

2 September 2017

publication date

12 February 2003

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

46

1 reference

Europe PubMed Central

2 September 2017

2

1 reference

Europe PubMed Central

2 September 2017

222-230

1 reference

Europe PubMed Central

2 September 2017

https://scigraph.springernature.com/pub.10.1007/s00125-002-1028-x

0 references

Pancreatic B-cells as mediators of metabolic effects of regulatory peptides

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

The metabolic role of GIP: physiology and pathology

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Glucagon-like peptide-1 is a physiological incretin in rat

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00125-002-1028-X

21 January 2018

Pancreatic alpha- and beta-cell responses to GIP infusion in normal man

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagonlike peptide 1: a newly discovered gastrointestinal hormone

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of glucose by an automatic analyser

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glucagon-like peptide-1 on insulin secretion

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel [...]

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of GIP and GLP-1 antagonists on insulin release in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/12627321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-002-1028-X

0 references

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38356895&oldid=1509442715"